Andrea Marzi

SLR14, an immunomodulatory RIG-I agonist, provides broad-spectrum antiviral protection against multiple highly pathogenic negative-sense RNA viruses in vitro and in vivo.

The paper develops a murine model of in utero Ebola virus transmission and shows placental infection and fetal transmission occur within 2-3 days post-infection.

A single-dose VSV-BDBV vaccine protects macaques from BDBV challenge within 3 days by inducing neutralizing antibodies and Fc effector function.

This study evaluates the protective efficacy of low-dose VSV-EBOV vaccines in nonhuman primates, finding reduced protection with a Makona GP vaccine compared to a Kikwit GP vaccine.

This study shows that acute malaria infection reduces the effectiveness of a low-dose Ebola vaccine by impairing antibody responses in lymph node macrophages, which can be mitigated with higher vaccine doses.

A single dose of VSV-SUDV vaccine protected macaques from lethal SUDV infection within one week, while VSV-EBOV provided no cross-protection.

This study shows Jamaican fruit bats can support EBOV replication and shedding but not MARV, due to differences in viral entry and IFN-I signaling suppression.

This paper demonstrates a viral vaccine strategy using BCG-induced Th cells to enhance antibody responses against Ebola virus, providing protection in a mouse model.